Evaluating the efficacy of Munzij wa Mushile Balgham in halting the progression of Rheumatoid arthritis

Evaluating the efficacy of Munzij wa Mushile Balgham in halting the progression of Rheumatoid arthritis - nil

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/05/087719

Enrollment

Registered

2025-05-27

Start date

Unknown

Completion date

Unknown

Last updated

2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M958- Other specified acquired deformities of musculoskeletal system

Interventions

Intervention1: Munzij wa Mushil Therapy: Munzije Balgham: NAME, BOTANICAL NAME, PART USAGE and DOSES 1-Gul-e-Banafsha Flower of Viola odorata Flower 7gm, 2-Badiyan Foeniculum vulgare Seed 4gm, 3-Tukh

Eligibility

Inclusion criteria

Inclusion criteria: 1-Clinically diagnosed patients through 1987 American College of Rheumatology Revised Criteria 2-Clinically stable patients

Exclusion criteria

Exclusion criteria: 1-Unstable, bed ridden and mentally retard patients 2-Patients less than 15 year and more than 70 years of age group 3-Persons having Gout/Osteo Arthritis 4-Pregnant/lactating women 5-Patients having malignancy 6-Patients do not report for follow up 7-Patient who does not willing to participate in the study

Design outcomes

Primary

Measure	Time frame
Visual analogue scale(VAS) RA factor (Quantitative) Anti CCP ESR CRP Timepoint: 180 days	—

Secondary

Measure	Time frame
Morning Stiffness Pain Arthritis in 3 or more joints Rheumatic nodules Restriction of movement Tenderness Timepoint: 180 days	—

Countries

India

Contacts

Public ContactMd Tanwir Alam

Govt Tibbi College and Hospital Kadam Kuan Patna 800003

tanveernium3133@gmail.com7543854407

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026